Longport, Inc (LPTI) Fair Value & Analysis
Healthcare · US · Market cap $2.3K
Longport, Inc
LPTI · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.1800 to $0.0001 (−99.9%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0001 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Longport, Inc (LPTI) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $1.2M. Fundamentals as of Jun 26, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Longport, Inc. develops, manufactures, markets, and sells high resolution ultrasound imaging systems primarily in the United States. It offers EPISCAN I-200, a high frequency ultrasound imaging system that utilizes ultrasound at frequencies between 20 and 50MHz to image the skin and underlying soft tissue. The company's products are used in wound assessment, wound prevention, clinical dermatology, and aesthetics/plastics, as well as in various other applications, including burn assessment, superficial musculoskeletal imaging, and veterinary applications. It also exports its products. The company was founded in 1993 and is based in Chadds Ford, Pennsylvania.
Revenue & earnings trend
FY2000 – FY2004 · reported fiscal years
Longport, Inc reported revenue of $2.5M in FY2004 versus $281K in FY2000, a compound +72.0%/yr. Reported net income was −$634K in FY2004.
Is LPTI fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.50 | €33.99 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Longport, Inc (LPTI) undervalued?
What is the fair value of LPTI?
What is the quality score of LPTI?
What is the revenue of Longport, Inc (LPTI)?
What is the net profit margin of LPTI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.